- Dan
Handley brings wealth of invaluable experience to POAI’s board of
directors
- Newest
board member has extensive experience with entities closely associated
with POAI’s Helomics division
- Predictive
Oncology set to benefit from Handley’s broad knowledge, expertise
Predictive Oncology Inc. (NASDAQ: POAI), a leader in the
cancer precision-medicine field, has announced the unanimous appointment of its
newest board member (http://ibn.fm/bK1Pr).
Dr. Dan Handley, MS, PhD, brings a wealth of invaluable experience to POAI’s
already impressive board of directors.
“Predictive Oncology is once again very fortunate to
announce another exemplary addition to our Board of Directors,” POAI CEO Dr.
Carl Schwartz stated in a news release. “Dan Handley has a varied and strong
background, including interaction with Carnegie Mellon University and
Magee-Women’s Research Institute – both leaders in their respective fields and
closely associated with our Helomics division. I greatly anticipate working
with Dan and benefitting from his knowledge and experience.”
Currently serving as a professor and the director of the
Clinical and Translational Genome Research Institute of Southern California
University of Health Sciences, Handley has also served as chief scientific
officer of the Clinical and Translational Genome Research Institute, a Florida
501(c)3 nonprofit corporation. During his time at the Genome Research
Institute, Handley held a courtesy faculty appointment in the Department of
Biological Sciences at Florida Gulf Coast University.
Other roles Handley has filled include chief scientific
officer for Advanced Healthcare Technology Solutions Inc.; senior researcher at
Procter & Gamble; senior administrator, researcher and laboratory manager
at the David Geffen UCLA School of Medicine; and a founding biotechnology
inventor for the National Genetics Institute.
Handley holds a BA in biophysics from Johns Hopkins
University, an MS in logic and computation from Carnegie Mellon University and
a PhD in human genetics from the University of Pittsburgh. In addition, he
completed his postdoctoral training at Magee-Women’s Research Institute where
his research focused on advanced genomic technologies applied to fetal and
maternal health. A decorated veteran, Handley served as a nuclear propulsion
instructor and a submarine nuclear reactor operator during his time with the
U.S. Navy.
POAI is bringing precision medicine, or tailored
medical treatment using the individual characteristics of each patient, to the
treatment of cancer. Through its Helomics division, the company leverages its
unique, clinically validated patient derived (PDx) smart tumor profiling
platform to provide oncologists with a roadmap to help individualize therapy.
In addition, the company is leveraging artificial intelligence and its
proprietary database of over 150,000 cancer cases tumors to build
AI-driven models of tumor drug repose to improve outcomes for the patients of
today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
